1 / 3

CBZ:saccharin CBZ:nicotinamide

diana-schultz
Télécharger la présentation

CBZ:saccharin CBZ:nicotinamide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Basic research in solid-state chemistry leads to new formulations for drugs:The nature of pharmaceutical molecules means that they inherently contain functional groups that engage in molecular recognition events. These functional groups can be exploited in order to design binary crystalline compounds, co-crystals, a hitherto lightly studied class of compounds. New formulations of the drug carbamazepine, CBZ, are illustrated on this and the following slide. From Molecular Polygons to Discrete Faceted Polyhedra to Porous Frameworks Mike Zaworotko, University of South Florida,DMR-0101641 CBZ:saccharin CBZ:nicotinamide

  2. CBZ:formic CBZ:acetic CBZ:butyric These new formulations are now being developed via a partnership with Transform Pharmaceuticals of Lexington, Massachusetts. The research also has relevance in the context of solid-state synthesis of organics and novel organic polymers. Crystal Growth & Design, 3, 909-919, 2003; Chem. Commun., in press; Z. fur Krist., 2004, submitted.

  3. From Molecular Polygons to Discrete Faceted Polyhedra to Porous Frameworks Mike Zaworotko, University of South Florida,DMR-0101641 Education: Three undergraduates, seven graduate students (Gregory McManus, Heba Abourahma, John Perry, Beth Rather, Jiangjiang Lu, Rick Wang and Brian Moulton), and one postdoc (Victor Kravstov) contributed to this work in year 3 of the grant. Rather, Abourahma, Moulton and Lu all received Ph.D.’s in 03-04. Moulton is now a faculty member at Brown University. Abourahma (Iowa), Lu (Argonne) and Rather (Oregon) all have post-doctoral fellowships. Publications: > 35 peer-reviewed publications since 2001. Over 3000 citations since 01/00 including a 2001 review article which was determined by ISI to be the #1 hot paper in Chemistry in July 2003 (574 cites as of 08/04). • Synergy: • Industrial interaction since 1998. Funded research with six companies. • Organizer of 12 symposia or conferences in U.S./Canada. • UTEK Corporation’s Scientific Advisory Council, Member of Transform Pharmaceutical’s Scientific Advisory Board. • Founding Editor of Crystal Engineering, published by Elsevier; Editorial Board; J. Chemical Crystallography, Crystal Growth & Design. • Papers reviewed for many journals including Science, Nature, JACS, Angewandte Chemie in 2003/2004. • Participant in Challenges for the Chemical Sciences in the 21st Century, 2002. • Served on nanotechnology panels for Canadian Foundation for Innovation and NSF/EPSCOR in 2003.

More Related